Lotus Eye Hospital and Institute financials

·Pharma & HealthChart ›
Latest results Q1 FY27 · Apr–Jun 2026
Revenue
₹17.1cr+26.2% on Q1 FY26
Net profit
₹0.6cr+12.6% on Q1 FY26
EBITDA margin
17.3%+6.3 pts on Q1 FY26
EPS
₹0.30+15.4% on Q1 FY26

Quarterly results

Every quarter ›
₹ croreQ1 FY27Q1 FY26Change
Revenue17.113.5+26.2%
EBITDA2.91.5+99.5%
EBITDA margin17.3%10.9%+6.3 pts
Profit before tax1.00.7+38.4%
Net profit0.60.5+12.6%
EPS₹0.30₹0.26+15.4%

Over time

Q1 FY27 · Apr–Jun 2026latest
Revenue₹17.1 crNet profit₹0.6 crNet margin3.6%

Amounts on the left scale in ₹ crore; per cent on the right, dashed. L = lakh crore, K = thousand crore. Touch the chart to read any period.

Key numbersby financial year

₹ crore except per share
Tap a line for its trendCurrentlast 12MFY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
228————
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
1.81.82.02.73.6
11.411.40.00.00.0
237————
57.353.749.648.247.0
—+8.4%+2.8%+2.5%—
4.93.43.46.57.6
8.5%6.3%6.9%13.6%16.1%
0.3−0.40.42.84.6
0.10.10.72.94.1
0.3%0.2%1.5%6.1%8.7%
₹0.07₹0.04₹0.36₹1.40₹1.96
—−89.1%−74.6%−28.5%—
—3.14.95.74.4
—−13.0−4.8−5.6−3.1
−9.9−9.90.10.01.3
Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

LOTUSEYE₹109.54

Lotus Eye Hospital and Institute Limited

· Pharma & Health
₹ CrorePeersGPTHEALTHGKSLSHALBYINDRAMEDCOARTEMISMEDDRAGARWQKMCSHILKOVAIMcap ₹228 Cr
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
In ₹ Crore except Per Share
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Current/LTM
TTM · last close
Market Capitalization————227.8
- Cash, Equiv & ST Investments3.62.72.01.81.8
+ Total Debt0.00.00.011.411.4
Enterprise Value————237.4
Revenue47.048.249.653.757.3
Growth %, YoY—+2.5+2.8+8.4—
EBITDA7.66.53.43.44.9
Margin %16.1313.556.936.308.47
EBIT4.62.80.4-0.40.3
Net Income4.12.90.70.10.1
Margin %8.676.051.490.150.26
EPS, Adj (current shares)1.961.400.360.040.07
Growth %, YoY—-28.5-74.6-89.1—
Cash from Operations4.45.74.93.1—
Capital Expenditures-3.1-5.6-4.8-13.0—
Free Cash Flow1.30.00.1-9.9-9.9
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.

Lotus Eye Hospital and Institute financials and key ratios

Prices at the 29 October 2026 close · figures from the company's filings with NSE

Lotus Eye Hospital and Institute (NSE: LOTUSEYE) had a market capitalisation of ₹229 crore at the 29 October 2026 close (₹110.00 a share), a PE ratio of 1,532.2 on the last four quarters' profit and a price-to-book ratio of 3.80. In FY26 its consolidated net profit was ₹8 lakh on revenue of ₹53.7 crore; in Q1 FY27 (April–June 2026) it was ₹61 lakh, up 12.6% year on year. Its debt-to-equity ratio was 0.19 on 31 March 2026. Promoters held 40.14% of the shares on 30 September 2026.

Share price used
₹110.00 · 29 October 2026 close
Latest balance sheet
31 March 2026
Shareholding pattern
30 September 2026

Lotus Eye Hospital and Institute at a glance · consolidated

Market cap
₹229 Crat ₹110.00 · 29 Oct close
PE ratio (last 4 quarters)
1,532.22,845.3 on FY26 profit
Price to book (PB)
3.80book value ₹28.92 a share
ROE (FY26)
0.1%−1.1 pts vs FY25ROCE −0.5%
Debt to equity
0.19net debt ₹7.6 Cr
Promoter holding
40.14%unchanged vs 30 Jun 202630 September 2026
Net worth
₹60.1 Cr+0.2% vs 31 Mar 202531 March 2026
Free cash flow (FY26)
−₹9.9 Cr
EPS (FY26)
₹0.04

Questions

What is the Lotus Eye Hospital and Institute PE ratio today?

Lotus Eye Hospital and Institute's PE ratio is 1,532.2 at the 29 October 2026 close (₹110.00 a share): a market capitalisation of ₹229 crore divided by consolidated net profit of ₹15 lakh over the last four quarters (Q2 FY26 to Q1 FY27). On FY26 net profit (₹8 lakh) it is 2,845.3.

What is the Lotus Eye Hospital and Institute PB ratio (price to book value)?

Lotus Eye Hospital and Institute's price-to-book (PB) ratio is 3.80 at the 29 October 2026 close: a market capitalisation of ₹229 crore divided by shareholders' equity (book value) of ₹60.1 crore on 31 March 2026. That is a book value of ₹28.92 per share against a share price of ₹110.00.

What is the Lotus Eye Hospital and Institute net worth?

Lotus Eye Hospital and Institute's net worth — shareholders' equity in its consolidated balance sheet — was ₹60.1 crore on 31 March 2026, up 0.2% from ₹60 crore a year earlier. Its market value is a different figure: a market capitalisation of ₹229 crore at the 29 October 2026 close.

What is the Lotus Eye Hospital and Institute market cap?

Lotus Eye Hospital and Institute's market capitalisation was ₹229 crore at the 29 October 2026 close: 2.08 crore shares at ₹110.00 each.

Is Lotus Eye Hospital and Institute debt free?

No. Lotus Eye Hospital and Institute had borrowings of ₹11.4 crore on 31 March 2026 (consolidated balance sheet), a debt-to-equity ratio of 0.19. Its cash and current investments were ₹3.8 crore, so its net debt was ₹7.6 crore.

What is the Lotus Eye Hospital and Institute debt to equity ratio?

Lotus Eye Hospital and Institute's debt-to-equity ratio was 0.19 on 31 March 2026: borrowings of ₹11.4 crore against total equity of ₹60.1 crore. A year earlier, on 31 March 2025, it was 0.00.

What is the Lotus Eye Hospital and Institute ROE and ROCE?

In FY26, Lotus Eye Hospital and Institute's return on equity (ROE) was 0.1% and its return on capital employed (ROCE) was −0.5%. ROE is net profit divided by average shareholders' equity (the start and end of the year); ROCE is operating profit (EBIT) divided by average capital employed (total assets less current liabilities). In FY25, ROE was 1.2% and ROCE 0.7%.

What is the Lotus Eye Hospital and Institute book value per share?

Lotus Eye Hospital and Institute's book value per share was ₹28.92 on 31 March 2026: shareholders' equity of ₹60.1 crore divided by the 2.08 crore shares in issue, up 0.2% from ₹28.85 a year earlier. The share price at the 29 October 2026 close was ₹110.00.

What is the Lotus Eye Hospital and Institute promoter holding?

Promoters held 40.14% of Lotus Eye Hospital and Institute on 30 September 2026, unchanged from the previous quarter and down 0.50 percentage points from 40.64% a year earlier, according to the shareholding pattern filed with NSE.

What is the Lotus Eye Hospital and Institute EPS?

Lotus Eye Hospital and Institute's basic earnings per share (EPS) were ₹0.04 in FY26, against ₹0.36 in FY25. Over the last four quarters (Q2 FY26 to Q1 FY27) they add up to ₹0.08.

What is the Lotus Eye Hospital and Institute shareholding pattern?

On 30 September 2026, Lotus Eye Hospital and Institute's shares were held by promoters 40.14%, domestic institutions (DII) 0.02% and retail and other non-institutional investors 59.85%. Over the year, DII holding was unchanged.

When are the Lotus Eye Hospital and Institute next results?

Lotus Eye Hospital and Institute has not yet announced the date of its Q2 FY27 results (July–September 2026); under SEBI's listing rules (Regulation 33) they are due by 14 November 2026.

What is the Lotus Eye Hospital and Institute free cash flow?

In FY26, Lotus Eye Hospital and Institute generated ₹3.1 crore of cash from operations and spent ₹13 crore on capital expenditure (property, plant, equipment and intangibles), leaving free cash flow of −₹9.9 crore. In FY25 it was ₹12 lakh.

What are the Lotus Eye Hospital and Institute latest quarterly results?

Lotus Eye Hospital and Institute's latest results are for Q1 FY27 (April–June 2026), filed on 10 August 2026: consolidated net profit ₹61 lakh, up 12.6% from ₹54 lakh in Q1 FY26; revenue from operations ₹17.1 crore, up 26.2% year on year.

What is the Lotus Eye Hospital and Institute revenue and profit in FY26?

In FY26 (April 2025–March 2026), Lotus Eye Hospital and Institute's consolidated net profit was ₹8 lakh, down 89.1% from ₹74 lakh in FY25, on revenue from operations of ₹53.7 crore (up 8.4%). Over three years, from FY23, net profit was down 98.0%.

How does Lotus Eye Hospital and Institute compare with its peers?

On FY26 consolidated figures, against GPT Healthcare, Gujarat Kidney And Super Speciality and Shalby: Lotus Eye Hospital and Institute's operating margin of −0.7% is the lowest of the four (GPT Healthcare 12.1%, Gujarat Kidney And Super Speciality 27.1%, Shalby 6.4%; peer average 15.2%); its return on equity of 0.1% is the lowest of the four (GPT Healthcare 16.3%, Gujarat Kidney And Super Speciality 6.1%, Shalby 3.7%; peer average 8.7%).

How does the Lotus Eye Hospital and Institute PE ratio compare with its peers?

At the 29 October 2026 closing prices, on FY26 net profit, Lotus Eye Hospital and Institute's PE ratio is 2,845.3, the highest of the four: GPT Healthcare 26.6, Gujarat Kidney And Super Speciality 87.4 and Shalby 35.1, a peer average of 49.7. Each is the company's market capitalisation at that price divided by its FY26 net profit.

Lotus Eye Hospital and Institute vs GPT Healthcare: how do they compare?

In FY26, Lotus Eye Hospital and Institute earned net profit of ₹8 lakh on revenue of ₹53.7 crore, against ₹42.2 crore on ₹473 crore for GPT Healthcare. Lotus Eye Hospital and Institute's operating margin was −0.7% (GPT Healthcare 12.1%) and its return on equity 0.1% (GPT Healthcare 16.3%). At the 29 October 2026 close, Lotus Eye Hospital and Institute's market capitalisation was ₹229 crore against ₹1,123 crore for GPT Healthcare, and its PE ratio on FY26 profit 2,845.3 against 26.6.

Where do these Lotus Eye Hospital and Institute figures come from?

From Lotus Eye Hospital and Institute's own consolidated results, balance sheets and shareholding patterns filed with NSE, and NSE prices (the latest used here: the 29 October 2026 close). Ratios are calculated by Alphave from those filings as each answer describes.

Consolidated figures from the company's filings with NSE; prices are NSE closing prices.